Market Overview:
Respiratory Inhalers are medical devices used to deliver medication directly into the lungs, providing quick relief for respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. These inhalers offer several advantages over traditional oral medications, such as targeted drug delivery, reduced side effects, and faster action. The rising prevalence of respiratory diseases, increasing air pollution levels, and the growing aging population are driving the demand for respiratory inhalers globally.
Market Key Trends:
One key trend in the respiratory inhaler market is the shift towards digital inhalers and connected devices. Digital inhalers, also known as smart inhalers, are equipped with sensors and Bluetooth technology that track medication usage, provide reminders for inhaler doses, and monitor the patient's condition remotely. These devices offer benefits such as improved medication adherence, real-time data monitoring, and personalized treatment plans. The integration of digital technologies with respiratory inhalers is expected to enhance patient compliance, reduce hospitalizations, and improve overall disease management. Major players in the market are investing in the development of smart inhaler technologies and partnering with digital healthcare companies to capitalize on this emerging trend.
The global Respiratory Inhaler Market Demand is estimated to be valued at US$ 28.2 Billion in 2023 and is expected to exhibit a CAGR Of 4.8% over the forecast period of 2023-2032, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis:
The respiratory inhaler market can be segmented based on product type, technology, application, and end-user. In terms of product type, metered dose inhalers (MDIs) dominate the market. MDIs are widely used due to their ease of use and portability. They deliver a pre-measured dose of medication and are available for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). MDIs are used by patients of all ages, including children and the elderly, making them the dominating sub-segment in the respiratory inhaler market.
Key Takeaways:
The global respiratory inhaler market is expected to witness high growth, exhibiting a CAGR of 4.8% over the forecast period (2023-2032). This growth can be attributed to the increasing prevalence of respiratory diseases such as asthma and COPD. The rising pollution levels, smoking habits, and sedentary lifestyles are contributing to the higher incidence of these respiratory conditions, leading to an increased demand for respiratory inhalers.
In terms of regional analysis, North America is the fastest-growing and dominating region in the respiratory inhaler market. This can be attributed to the high prevalence of respiratory diseases and the presence of well-established healthcare infrastructure in the region. The increasing healthcare expenditures and favorable reimbursement policies further contribute to the growth of the market in North America.
Key players operating in the respiratory inhaler market include AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd. These key players are focusing on product innovations, collaborations, and mergers to strengthen their market presence and gain a competitive edge. The increasing investments in research and development activities to develop novel drugs and devices for respiratory diseases are also driving the growth of the market.
Global respiratory inhaler device shipments are likely to grow at over 4% in 2021, as the medical device industry makes a gradual recovery.
This stark contrast reflects the status-quo in the global medical device industry, where realization of new investment and bottom-lines are concurrent.Global demand for respiratory inhaler devices continues to be driven by rising prevalence of COPD and asthma.
According to the World Health Organization (WHO), nearly 251 million cases of chronic obstructive pulmonary disease (COPD) were reported worldwide in 2016 and nearly 339 million people were estimated to have asthma in the same year.
Spurred by these factors, the global market for respiratory inhaler devices is expected to report surging sales.Smart Inhaler Technology Touted as a Major BreakthroughSmart inhalers have been touted as a disruptive technology, and it remains a key focus area for manufacturers.
Smart inhalers can signal patients if their overusing any medication, warning them against poor management of the condition.
The technology is touted as a major breakthrough in the healthcare sector and one that is expected to enable growth in the respiratory inhaler devices market in the coming years.Several studies already are underway gauging the potential of these development.
Pune, India – August 28, 2018 —
The Global Asthma Inhaler Device Market has been observing continued growth and is expected to capture a CAGR of 5.2% over the forecast period of 2017–2023, reveals Market Research Future (MRFR), in a minutely analyzed research report.
The high incidence rate of respiratory disorders, particularly COPD and asthma spur the market growth.
LTD. (India), Merck & Co., Inc. (US), Aristopharma Ltd. (Bangladesh), and Intas Pharmaceuticals, Ltd. (India).
Asthma Inhaler Device Market – Updates
May 2018, a new asthma device which requires less force to activate has been created by engineers at the University of Cape Town.
